Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that GSK plc made materially false and/or misleading statements and/or failed to disclose that: GSK issued a press release on July 17, 2025, announcing "that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations." Following this news, GSK's American Depositary Receipt ("ADR") price fell over 4% on July 17, 2025.
In order to be eligible to join the GSK class action lawsuit, you must have incurred a loss on shares of GSK plc purchased during the class period listed above.
TOP
